-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 7, 2021 , CDE's official website showed that AstraZeneca's PARP1 selective inhibitor was approved for clinical use in advanced malignant solid tumors .
On September 7, CDE's official website showed that AstraZeneca's PARP1 selective inhibitor was approved for clinical use in advanced malignant solid tumors
PARP, namely polyADP-ribose polymerase (poly ADP-ribose polymerase), is a kind of ribozyme that exists in eukaryotic cells and catalyzes the synthesis of poly(ADP-ribose) [PAR].
Part of the adverse reactions of the first-generation dual PARP1/2 inhibitor (PARPi) may come from the inhibition of PARP2, which is not necessary for efficacy
First report of PETRA (NCT04644068) trial results
breast cancer ovarian cancer pancreatic cancer
As of November 17, 2021, 46 patients were taking AZD5305 10-90 mg orally daily (43.
At 10-40mg QD dose, AZD5305 inhibited ≥90% polyadenosine diphosphate ribosylation (PARylation), confirming its effective binding to the target
Results published last year showed that AZD5305 caused accumulation of DNA damage only in BRCA mutant cells and was not harmful to BRCA wild-type cells; in animal experiments, the antitumor activity of AZD5305 at a dose of 0.
AZD5305 caused accumulation of DNA damage only in BRCA mutant cells, but was not harmful to BRCA wild-type cells; in animal experiments, the antitumor activity of AZD5305 at 0.
leave a message here
